Valuation: AstraZeneca PLC

Market Cap 259B 226B 214B 194B 363B 24,882B 365B 2,557B 987B 12,650B 974B 952B 40,704B P/E 2026 *
21.3x
P/E 2027 * 18.6x
Enterprise Value 279B 243B 230B 209B 391B 26,771B 392B 2,752B 1,062B 13,611B 1,048B 1,025B 43,795B EV / Sales 2026 *
4.42x
EV / Sales 2027 * 4.05x
Free-Float
96.63%
Yield 2026 *
1.99%
Yield 2027 * 2.12%
1 day+0.59%
Current year+1.81%
Current year 152.4
Extreme 152.4
166.3
1 year 124.15
Extreme 124.15
166.3
3 years 111
Extreme 111
166.3
5 years 95.25
Extreme 95.25
166.3
10 years 47.72
Extreme 47.715
166.3
Manager TitleAgeSince
Chief Executive Officer 66 30/09/2012
Director of Finance/CFO 52 31/07/2021
Compliance Officer - 31/12/2022
Director TitleAgeSince
Director/Board Member 70 05/04/1999
Director/Board Member 66 30/09/2012
Director/Board Member 65 26/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.59%-.--% - - 259B
+0.04%+3.34%+51.12%+101.82% 1,028B
-0.09%+1.66%+55.02%+66.18% 651B
-0.02%+2.66%+18.91%+71.47% 466B
-1.22%+3.66%+36.44%+38.32% 346B
-0.79%+2.73%+19.03%+25.08% 266B
+0.58%+6.76%+11.13%+16.52% 259B
+1.55%+2.20%+39.81%+46.55% 208B
+0.79%+1.84%-28.27%-56.71% 191B
-0.52%+4.45%+32.12%+98.51% 186B
Average +0.24%+3.26%+26.15%+45.30% 400.19B
Weighted average by Cap. +0.26%+3.09%+35.15%+61.76%

Financials

2026 *2027 *
Net sales 63.12B 55.04B 51.97B 47.19B 88.42B 6,057B 88.79B 623B 240B 3,079B 237B 232B 9,908B 66.98B 58.4B 55.15B 50.08B 93.82B 6,427B 94.22B 661B 255B 3,267B 252B 246B 10,513B
Net income 12.07B 10.53B 9.94B 9.03B 16.91B 1,158B 16.98B 119B 45.94B 589B 45.35B 44.34B 1,895B 13.8B 12.04B 11.37B 10.32B 19.34B 1,325B 19.42B 136B 52.54B 673B 51.85B 50.7B 2,167B
Net Debt 19.69B 17.17B 16.22B 14.73B 27.59B 1,890B 27.7B 194B 74.96B 961B 73.98B 72.34B 3,091B 11.93B 10.4B 9.82B 8.92B 16.71B 1,145B 16.78B 118B 45.41B 582B 44.82B 43.82B 1,873B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
167.18USD
Average target price
211.39USD
Spread / Average Target
+26.44%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!